NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Asthma And COPD Medicines Market Size, Share and Trends Analysis

Global Asthma and COPD Medicines Market size reached $55.2B in 2023, projected to grow at 5.0% CAGR to $85.7B by 2032. Key drivers include rising disease prevalence, aging populations, and technological innovations in inhalation therapies.

Revenue, 2023

$55.2B

Forecast, 2032

$85.7B

CAGR, 2024-2032

5%

Report Coverage

North America

Code: asthma-and-copd-medicines-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The asthma and COPD medicines market is experiencing robust growth driven by increasing disease prevalence and expanding treatment options, with a projected CAGR of 5.0% from 2024 to 2032, reaching $85.7 billion by 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Rise of biologic therapies targeting specific inflammatory pathwaysIncreased adoption of fixed-dose combination inhalersDigital health integration for treatment adherence monitoringGrowing focus on personalized medicine approaches
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 5%

Base Year (2023)

$57.8B

Forecast (2032)

$85.7B

CAGR (2024-2032)

5%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 40.5%CAGR: 4.8%

Largest market: United States

Europe

#2
Share: 35.2%CAGR: 4.3%

Largest market: Germany

03

Market Dynamics

  • Increasing global prevalence of respiratory diseases due to urbanization and air pollution
  • Aging population requiring long-term respiratory management
  • Advancements in inhalation device technology improving patient adherence
  • Rising healthcare expenditure in emerging markets
04

Market Segmentation

05

Regional Analysis

1

North America

Lead: United States
CAGR: 4.8%Share: 40.5%

Dominates the global market due to high adoption rates of advanced therapies and robust reimbursement systems.

2

Europe

Lead: Germany
CAGR: 4.3%Share: 35.2%

Stable market with significant growth driven by new biologic approvals and strong healthcare infrastructure.

3

Asia Pacific

Lead: China
CAGR: 6.1%Share: 24.3%

Fastest-growing region due to rising urbanization, increasing pollution levels, and expanding healthcare access.

Country-Level Analysis

CountryShareGrowth
United States
22.1%
+4.5%
Germany
11.8%
+4.1%
China
9.7%
+6.8%
06

Competitive Landscape

G

GlaxoSmithKline

United Kingdom

Leader60.3B

Dominates with extensive respiratory portfolio including Advair, Symbicort, and Breo Ellipta

Advair DiskusSymbicortBreo Ellipta
A

AstraZeneca

Sweden

Leader52.7B

Strong position with Symbicort, Breo Ellipta, and emerging biologics pipeline

SymbicortBreo ElliptaFasenra
T

Teva Pharmaceutical

Israel

Challenger12.8B

Leading generic provider with significant presence in asthma/COPD markets

AlbuterolFluticasoneSalmeterol
B

Boehringer Ingelheim

Germany

Challenger

Strong in LAMA segment with Spiolto and developing novel biologics

P

Pfizer

United States

Follower

Significant player with Serevent and expanding respiratory portfolio

07

Recent Developments

25
2025AstraZeneca

Received FDA approval for Fasenra (benralizumab) for severe eosinophilic asthma in pediatric patients

24
2024GlaxoSmithKline

Launched Advair HFA 200/21 with improved dose accuracy and patient adherence features

24
2024Boehringer Ingelheim

Initiated Phase III trials for novel LAMA/LABA combination therapy for COPD

24
2024Teva

Secured regulatory approval for generic version of Symbicort in European markets

08

Regulatory Landscape

FDA's 2023 guidance on accelerated approval pathways for severe asthma biologicsEMA's 2024 review of fixed-dose combination inhaler safety standardsGlobal IP protection challenges for biologic therapies
09

Frequently Asked Questions

The market was valued at $55.2 billion in 2023 and is projected to reach $85.7 billion by 2032.
The market is expected to grow at a CAGR of 5.0% from 2024 to 2032.
North America holds the largest market share at 40.5%, followed by Europe at 35.2% and Asia Pacific at 24.3%.
Key drivers include increasing global prevalence of respiratory diseases, aging populations, advancements in inhalation technology, and rising healthcare expenditure in emerging markets.